Annual report
4886.TEDINET S100OHVN
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 37
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥6.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥44.5bn | at 2021-03-31 | Cons. | Net assets |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 777 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥682m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥41.3bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥606m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.7bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥820m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 74 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 48 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥5.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥360m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥136m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥37.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥653m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | employees | at 2022-03-31 | 649 pure |
| Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-03-31 | ¥42.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥56.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥56.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥46.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,041
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in inventories ope cf | CurrentYearDuration | -687000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | 412000000 | JPY |
| Other net ope cf | CurrentYearDuration | 503000000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 4863000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 292000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -58000000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -1385000000 | JPY |
| Payments of contract termination ope cf | CurrentYearDuration | -870000000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 2842000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -579000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 10312000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYearDuration | -1798000000 | JPY |
| Purchase of investment securities inv cf | CurrentYearDuration | -56000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 11000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | CurrentYearDuration | -53000000 | JPY |
| Other net inv cf | CurrentYearDuration | -1091000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | 6743000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | -50000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -2298000000 | JPY |
| Net decrease increase in treasury stock fin cf | CurrentYearDuration | -248000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -398000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -2996000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | -0 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 6589000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 10514000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 17103000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 3 | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method | CurrentYearInstant | 3 | |
| Write down of inventories cost of sales | CurrentYearDuration | -343000000 | JPY |
| Salaries allowances and bonuses sga | CurrentYearDuration | 4218000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 719000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 490000000 | JPY |
| Haulage and warehousing expenses sga | CurrentYearDuration | 5767000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 3598000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 3598000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 50791000000 | JPY |
| Revenues from external customers | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5816000000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 56607000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 56607000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 73000000 | JPY |
| Transactions with other segments | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 73000000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -73000000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 50791000000 | JPY |
| Net sales | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5890000000 | JPY |
| Net sales | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 56681000000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -73000000 | JPY |
| Net sales | CurrentYearDuration | 56607000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |